SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS (DCSSC)

被引：2
|
作者：
Spiera, Robert [1 ]
Hummers, Laura [2 ]
Chung, Lorinda [3 ]
Frech, Tracy [4 ]
Domsic, Robin [5 ]
Hsu, Vivian [6 ]
Furst, Daniel [7 ,8 ]
Gordon, Jessica [1 ]
Mayes, Maureen [9 ]
Simms, Robert [10 ]
Lee, Elizabeth [11 ]
Constantine, Scott [11 ]
Dgetluck, Nancy [11 ]
White, Barbara [11 ]
机构：
[1] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA
[2] Johns Hopkins, Baltimore, MD USA
[3] Stanford Univ, Palo Alto, CA 94304 USA
[4] Univ Utah, Salt Lake City, UT USA
[5] Univ Pittsburgh, Pittsburgh, PA USA
[6] Univ Med & Dent New Jersey, New Brunswick, NJ USA
[7] Pacific Arthrit Associates, Los Angeles, CA USA
[8] Univ Calif Los Angeles, Los Angeles, CA USA
[9] Univ Texas Houston, Houston, TX USA
[10] Boston Univ, Boston, MA 02215 USA
[11] Corbus Pharmaceut Inc, Norwood, MA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.3390
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0325
引用
收藏
页码：245 / 245
页数：1
相关论文
共 50 条
  • [31] BRENTUXIMAB VEDONTIN FOR SKIN INVOLVEMENT IN REFRACTORY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, INTERIM RESULTS OF A PHASE IIB OPEN-LABEL TRIAL
    Fernandez-Codina, A.
    Nevskaya, T.
    Pope, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 103 - 104
  • [32] BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN SUBJECTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
    Khanna, D.
    Carreira, P.
    Chung, L.
    Denton, C. P.
    Matucci-Cerinic, M.
    Riemekasten, G.
    Mukai, S.
    Liu, S.
    Cai, S.
    Bogoslovsky, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1640 - 1641
  • [33] Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
    Sato, Takeo
    Inokuma, Shigeko
    RHEUMATOLOGY, 2010, 49 (08) : 1607 - 1607
  • [34] Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006)
    Hobbs, K.
    Wallace, D. J.
    Strand, V.
    Kalunian, K.
    Kilgallen, B.
    Bongardt, S.
    Wegener, W. A.
    Goldenberg, D. M.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S276 - S277
  • [35] Safety and efficacy of aceneuramic acid in GNE myopathy: open-label extension study
    Suzuki, Naoki
    Mori-Yoshimura, Madoka
    Katsuno, Masahisa
    Takahashi, Masanori P.
    Yamashita, Satoshi
    Oya, Yasushi
    Hashizume, Atsushi
    Yamada, Shinichiro
    Nakamori, Masayuki
    Izumi, Rumiko
    Kato, Masaaki
    Warita, Hitoshi
    Tateyama, Maki
    Kuroda, Hiroshi
    Asada, Ryuta
    Yamaguchi, Takuhiro
    Nishino, Ichizo
    Aoki, Masashi
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (11): : 1093 - 1094
  • [36] Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
    Doody, RS
    Geldmacher, DS
    Gordon, B
    Perdomo, CA
    Pratt, RD
    ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 427 - 433
  • [37] Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis–related pulmonary artery hypertension and cutaneous vascular complications
    Uma Kumar
    Sankalp S. Gokhle
    V. Sreenivas
    Satbir Kaur
    Durgaprasanna Misra
    Rheumatology International, 2013, 33 : 1047 - 1052
  • [38] Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study
    Chatham, W. Winn
    Furie, Richard
    Saxena, Amit
    Brohawn, Philip
    Schwetje, Erik
    Abreu, Gabriel
    Tummala, Raj
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (05) : 837 - 847
  • [39] Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension
    Giovannoni, Gavin
    Granziera, Cristina
    Mao-Draayer, Yang
    Cutter, Gary
    Kalbus, Oleksandr
    Staikov, Ivan
    Dufek, Michal
    Saubadu, Stephane
    Bejuit, Raphael
    Smyth, Brendan
    Djukic, Biljana
    Truffinet, Philippe
    Wallstroem, Erik
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 64 - 65
  • [40] Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial
    Craig, T. J.
    Reshef, A.
    Lumry, W. R.
    Saguer, I. Martinez
    Jacobs, J. S.
    Yang, W. H.
    Aygoren-Pursun, E.
    Keith, P. K.
    Busse, P.
    Magerl, M.
    Feuersenger, H.
    Bica, M. A.
    Glassman, F.
    Pragst, I.
    Levy, D. S.
    ALLERGOLOGIE, 2023, 46 (08) : 560 - 561
12345